Takeda Pharmaceuticals announced today it will globally discontinue two of its hemophilia treatments: HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. General information is available at HemophiliaJourney.com.
Download the Patient Letter
Treatment Transition Timeline
In a letter to patients dated March 18, 2025, Takeda stated it would continue to supply both medications to current patients until inventory is depleted or expires in mid-2026. The exact timing will vary based on potency and demand. The company emphasized there are no quality or safety issues with either product.
"This was not a decision we made lightly," wrote Anthea Cherednichenko, Vice President and Franchise Head of U.S. Hematology at Takeda. "As the treatment landscape evolves, we decided to discontinue these medicines as hemophilia patients continue to transition to alternate treatment options in the space, including those within our own hematology portfolio."
Alternatives for Patients
Takeda is directing patients to discuss alternative treatment plans with their healthcare providers. The company highlighted its two other factor VIII products as potential alternatives:
- ADVATE® [Antihemophilic Factor (Recombinant)]
- ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]
Both remaining treatments are indicated for the treatment and control of bleeding in children and adults with hemophilia A (congenital factor VIII deficiency) by Takeda. Please visit ADVATE.com and ADYNOVATE.com for more information.
Support Resources
Takeda has established support resources for affected patients:
- General information is available at HemophiliaJourney.com.
- Financial assistance options and insurance support can be accessed through Takeda Patient Support at TakedaPatientSupport.com or by calling 1-888-229-8379.
- Adverse reactions and quality issues can be reported at 1-877-TAKEDA-7 (1-877-825-3327).
We also encourage you to register for the Patient Notification System (PNS) if you haven't already. By signing up, you'll receive immediate alerts directly to your phone or email about any recalls or withdrawals of bleeding disorders therapies – ensuring you're always informed about changes that could affect your treatment.
NBDF remains dedicated to keeping our bleeding disorders community informed about important developments. We continuously monitor changes in treatment options, healthcare policies, medication recalls, and access issues that may impact your care. To ensure you receive these critical updates as they happen, we encourage you to connect with NBDF through our website, newsletter, and social media channels.
The National Bleeding Disorders Foundation (NBDF) does not provide medical advice or engage in the practice of medicine. NBDF does not endorse or recommend specific treatments for individuals. We strongly encourage all individuals to consult their physician or local treatment center before making any medical decisions or pursuing any course of treatment.
Source: Takeda
